Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00209430|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : October 31, 2007
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease Renal Impairment||Drug: Iodixanol 320 mgI/mL||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||408 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title.|
|Study Start Date :||August 2005|
- Peak increase in SCr
- Incidence of contrast media-induced nephropathy from baseline up to day 3.
- SCr concentrations up to days 3 and 7
- image quality
- occurrence of adverse events and their severity and relationship with the contrast media.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00209430
|Amersham Health S.A|
|Study Director:||Caroline Widlund, BSc RN||GE Healthcare|
|Study Director:||Johnny Gibbs, Jr., B.S., CCRA||609-514-6809|